Classification for avian malaria parasite Plasmodium gallinaceum blood stages by using deep convolutional neural networks.

The infection of an avian malaria parasite (Plasmodium gallinaceum) in domestic chickens presents a major threat to the poultry industry because it causes economic loss in both the quality and quantity of meat and egg production. Computer-aided diagnosis has been developed to automatically identify avian malaria infections and classify the blood infection stage development. In this study, four types of deep convolutional neural networks, namely Darknet, Darknet19, Darknet19-448 and Densenet201 are used to classify P. gallinaceum blood stages. We randomly collected a dataset of 12,761 single-cell images consisting of three parasite stages from ten-infected blood films stained by Giemsa. All images were confirmed by three well-trained examiners. The study mainly compared several image classification models and used both qualitative and quantitative data for the evaluation of the proposed models. In the model-wise comparison, the four neural network models gave us high values with a mean average accuracy of at least 97%. The Darknet can reproduce a superior performance in the classification of the P. gallinaceum development stages across any other model architectures. Furthermore, the Darknet has the best performance in multiple class-wise classification, with average values of greater than 99% in accuracy, specificity, and sensitivity. It also has a low misclassification rate (< 1%) than the other three models. Therefore, the model is more suitable in the classification of P. gallinaceum blood stages. The findings could help us create a fast-screening method to help non-experts in field studies where there is a lack of specialized instruments for avian malaria diagnostics.

Primaquine-thiazolidinones block malaria transmission and development of the liver exoerythrocytic forms.

BACKGROUND: Primaquine is an anti-malarial used to prevent Plasmodium vivax relapses and malaria transmission. However, PQ metabolites cause haemolysis in patients deficient in the enzyme glucose-6-phosphate dehydrogenase (G6PD). Fifteen PQ-thiazolidinone derivatives, synthesized through one-post reactions from primaquine, arenealdehydes and mercaptoacetic acid, were evaluated in parallel in several biological assays, including ability to block malaria transmission to mosquitoes. RESULTS: All primaquine derivatives (PQ-TZs) exhibited lower cell toxicity than primaquine; none caused haemolysis to normal or G6PD-deficient human erythrocytes in vitro. Sera from mice pretreated with the test compounds thus assumed to have drug metabolites, caused no in vitro haemolysis of human erythrocytes, whereas sera from mice pretreated with primaquine did cause haemolysis. The ability of the PQ-TZs to block malaria transmission was evaluated based on the oocyst production and percentage of mosquitoes infected after a blood meal in drug pre-treated animals with experimental malaria caused by either Plasmodium gallinaceum or Plasmodium berghei; four and five PQ-TZs significantly inhibited sporogony in avian and in rodent malaria, respectively. Selected PQ-TZs were tested for their inhibitory activity on P. berghei liver stage development, in mice and in vitro, one compound (4m) caused a 3-day delay in the malaria pre-patent period. CONCLUSIONS: The compound 4m was the most promising, blocking malaria transmissions and reducing the number of exoerythrocytic forms of P. berghei (EEFs) in hepatoma cells in vitro and in mice in vivo. The same compound also caused a 3-day delay in the malaria pre-patent period.

Artesunate-tafenoquine combination therapy promotes clearance and abrogates transmission of the avian malaria parasite Plasmodium gallinaceum.

Clinical manifestations of malaria infection in vertebrate hosts arise from the multiplication of the asexual stage parasites in the blood, while the gametocytes are responsible for the transmission of the disease. Antimalarial drugs that target the blood stage parasites and transmissible gametocytes are rare, but are essentially needed for the effective control of malaria and for limiting the spread of resistance. Artemisinin and its derivatives are the current first-line antimalarials that are effective against the blood stage parasites and gametocytes, but resistance to artemisinin has now emerged and spread in various malaria endemic areas. Therefore, a novel antimalarial drug, or a new drug combination, is critically needed to overcome this problem. The objectives of this study were to evaluate the efficacy of a relatively new antimalarial compound, tafenoquine (TQ), and a combination of TQ and a low dose of artesunate (ATN) on the in vivo blood stage multiplication, gametocyte development and transmission of the avian malaria parasite Plasmodium gallinaceum to the vector Aedes aegypti. The results showed that a 5-d treatment with TQ alone was unable to clear the blood stage parasites, but was capable of reducing the mortality rate, while TQ monotherapy at a high dose of 30mg/kg was highly effective against the gametocytes and completely blocked the transmission of P. gallinaceum. In addition, the combination therapy of TQ+ATN completely cleared P. gallinaceum blood stages and sped up the gametocyte clearance from chickens, suggesting the synergistic effect of the two drugs. In conclusion, TQ is demonstrated to be effective for limiting avian malaria transmission and may be used in combination with a low dose of ATN for safe and effective treatment.

Evidences for the action mechanism of angiotensin II and its analogs on Plasmodium sporozoite membranes.

Malaria is an infectious disease responsible for approximately one million deaths annually. Oligopeptides such as angiotensin II (AII) and its analogs are known to have antimalarial effects against Plasmodium gallinaceum and Plasmodium falciparum. However, their mechanism of action is still not fully understood at the molecular level. In the work reported here, we investigated this issue by comparing the antimalarial activity of AII with that of (i) its diastereomer formed by only d-amino acids; (ii) its isomer with reversed sequence; and (iii) its analogs restricted by lactam bridges, the so-called VC5 peptides. Data from fluorescence spectroscopy indicated that the antiplasmodial activities of both all-D-AII and all-D-VC5 were as high as those of the related peptides AII and VC5, respectively. In contrast, retro-AII had no significant effect against P. gallinaceum. Conformational analysis by circular dichroism suggested that AII and its active analogs usually adopted a ß-turn conformation in different solutions. In the presence of membrane-mimetic micelles, AII had also a ß-turn conformation, while retro-AII was random. Molecular dynamics simulations demonstrated that the AII chains were slightly more bent than retro-AII at the surface of a model membrane. At the hydrophobic membrane interior, however, the retro-AII chain was severely coiled and rigid. AII was much more flexible and able to experience both straight and coiled conformations. We took it as an indication of the stronger ability of AII to interact with membrane headgroups and promote pore formation.

A new factor in the Aedes aegypti immune response: CLSP2 modulates melanization.

Microbial infections in the mosquito Aedes aegypti activate the newly identified CLSP1 and CLSP2 genes, which encode modular proteins composed of elastase-like serine protease and C-type lectin domains. These genes are predominantly regulated by the immune deficiency pathway, but also by the Toll pathway. Silencing of CLSP2, but not CLSP1, results in the activation of prophenoloxidase (PPO), the terminal enzyme in the melanization cascade, suggesting that CLSP2 is a negative modulator of this reaction. Haemolymph PPO activation is normally inhibited in the presence of Plasmodium parasites, but in CLSP2-depleted mosquitoes, the Plasmodium-induced block of melanization is reverted, and these mosquitoes are refractory to the parasite. Thus, CLSP2 is a new component of the mosquito immune response.

Effects of Plasmodium gallinaceum on hemolymph physiology of Aedes aegypti during parasite development.

Insect disease vectors show diminished fecundity when infected with Plasmodium. This phenomenon has already been demonstrated in laboratory models such as Aedes aegypti, Anopheles gambiae and Anopheles stephensi. This study demonstrates several changes in physiological processes of A. aegypti occurring upon infection with Plasmodium gallinaceum, such as reduced ecdysteroid levels in hemolymph as well as altered expression patterns for genes involved in vitellogenesis, lipid transport and immune response. Furthermore, we could show that P. gallinaceum infected A. aegypti presented a reduction in reproductive fitness, accompanied by an activated innate immune response and increase in lipophorin expression, with the latter possibly representing a nutritional resource for Plasmodium sporozoites.

Wolbachia pipientis: an expanding bag of tricks to explore for disease control.

Wolbachia pipientis are maternally inherited, endosymbiotic bacteria that are widespread among insects. Two recent studies have demonstrated that Wolbachia inhibits the ability of medically significant pathogens, including filarial nematodes, dengue virus and Plasmodium to form infections in the mosquito vector, Aedes aegypti. We highlight the added value of these traits for Wolbachia based biocontrol strategies and evaluate the evidence for the idea that the insect immune response is responsible for the pathogen inhibition.

Apical surface expression of aspartic protease Plasmepsin 4, a potential transmission-blocking target of the plasmodium ookinete.

To invade its definitive host, the mosquito, the malaria parasite must cross the midgut peritrophic matrix that is composed of chitin cross-linked by chitin-binding proteins and then develop into an oocyst on the midgut basal lamina. Previous evidence indicates that Plasmodium ookinete-secreted chitinase is important in midgut invasion. The mechanistic role of other ookinete-secreted enzymes in midgut invasion has not been previously examined. De novo mass spectrometry sequencing of a protein obtained by benzamidine affinity column of Plasmodium gallinaceum ookinete axenic culture supernatant demonstrated the presence of an ookinete-secreted plasmepsin, an aspartic protease previously only known to be present in the digestive vacuole of asexual stage malaria parasites. This plasmepsin, the ortholog of Plasmodium falciparum plasmepsin 4, was designated PgPM4. PgPM4 and PgCHT2 (the P. gallinaceum ortholog of P. falciparum chitinase PfCHT1) are both localized on the ookinete apical surface, and both are present in micronemes. Aspartic protease inhibitors (peptidomimetic and natural product), calpain inhibitors, and anti-PgPM4 monoclonal antibodies significantly reduced parasite infectivity for mosquitoes. These results suggest that plasmepsin 4, previously known only to function in the digestive vacuole of asexual blood stage Plasmodium, plays a role in how the ookinete interacts with the mosquito midgut interactions as it becomes an oocyst. These data are the first to delineate a role for an aspartic protease in mediating Plasmodium invasion of the mosquito and demonstrate the potential for plasmepsin 4 as a malaria transmission-blocking vaccine target.

Proteomic analysis of zygote and ookinete stages of the avian malaria parasite Plasmodium gallinaceum delineates the homologous proteomes of the lethal human malaria parasite Plasmodium falciparum.

Delineation of the complement of proteins comprising the zygote and ookinete, the early developmental stages of Plasmodium within the mosquito midgut, is fundamental to understand initial molecular parasite-vector interactions. The published proteome of Plasmodium falciparum does not include analysis of the zygote/ookinete stages, nor does that of P. berghei include the zygote stage or secreted proteins. P. gallinaceum zygote, ookinete, and ookinete-secreted/released protein samples were prepared and subjected to Multidimensional protein identification technology (MudPIT). Peptides of P. gallinaceum zygote, ookinete, and ookinete-secreted proteins were identified by MS/MS, mapped to ORFs (> 50 amino acids) in the extent P. gallinaceum whole genome sequence, and then matched to homologous ORFs in P. falciparum. A total of 966 P. falciparum ORFs encoding orthologous proteins were identified; just over 40% of these predicted proteins were found to be hypothetical. A majority of putative proteins with predicted secretory signal peptides or transmembrane domains were hypothetical proteins. This analysis provides a more comprehensive view of the hitherto unknown proteome of the early mosquito midgut stages of P. falciparum. The results underpin more robust study of Plasmodium-mosquito midgut interactions, fundamental to the development of novel strategies of blocking malaria transmission.

Expression of a mutated phospholipase A2 in transgenic Aedes fluviatilis mosquitoes impacts Plasmodium gallinaceum development.

The genetic manipulation of mosquito vectors is an alternative strategy in the fight against malaria. It was previously shown that bee venom phospholipase A2 (PLA2) inhibits ookinete invasion of the mosquito midgut although mosquito fitness was reduced. To maintain the PLA2 blocking ability without compromising mosquito biology, we mutated the protein-coding sequence to inactivate the enzyme while maintaining the protein's structure. DNA encoding the mutated PLA2 (mPLA2) was placed downstream of a mosquito midgut-specific promoter (Anopheles gambiae peritrophin protein 1 promoter, AgPer1) and this construct used to transform Aedes fluviatilis mosquitoes. Four different transgenic lines were obtained and characterized and all lines significantly inhibited Plasmodium gallinaceum oocyst development (up to 68% fewer oocysts). No fitness cost was observed when this mosquito species expressed the mPLA2.

Exoerythrocytic development of Plasmodium gallinaceum in the White Leghorn chicken.

Plasmodium gallinaceum typically causes sub-clinical disease with low mortality in its primary host, the Indian jungle fowl Gallus sonnerati. Domestic chickens of European origin, however, are highly susceptible to this avian malaria parasite. Here we describe the development of P. gallinaceum in young White Leghorn chicks with emphasis on the primary exoerythrocytic phase of the infection. Using various regimens for infection, we found that P. gallinaceum induced a transient primary exoerythrocytic infection followed by a fulminant lethal erythrocytic phase. Prerequisite for the appearance of secondary exoerythrocytic stages was the development of a certain level of parasitaemia. Once established, secondary exoerythrocytic stages could be propagated from bird to bird for several generations without causing fatalities. Infected brains contained large secondary exoerythrocytic stages in capillary endothelia, while in the liver primary and secondary erythrocytic stages developed primarily in Kupffer cells and remained smaller. At later stages, livers exhibited focal hepatocyte necrosis, Kupffer cell hyperplasia, stellate cell proliferation, inflammatory cell infiltration and granuloma formation. Because P. gallinaceum selectively infected Kupffer cells in the liver and caused a histopathology strikingly similar to mammalian species, this avian Plasmodium species represents an evolutionarily closely related model for studies on the hepatic phase of mammalian malaria.

A expressão de WARP, um alvo potencial para Vacinas de Bloqueio de Transmissão, durante o desenvolvimento sexual de Plasmodium gallinaceum

Durante o ciclo de vida dos parasitos causadores da malária, uma das fases cruciais é o desenvolvimento sexual e a conseqüente invasão do epitélio intestinal do hospedeiro invertebrado. Proteínas dos estágios do ciclo esporogônico podem ser alvos para vacinas Bloqueadoras de Transmissão (TBVs). Uma das proteínas micronemais que já demonstrou ser um alvo promissor para a inibição do desenvolvimento de oocistos e, portanto, da transmissão, é a WARP (von Willebrand Factor A Domain Related Protein), uma proteína secretada, aparentemente envolvida com a adesão e locomoção dos parasitos. Estudos recentes demonstraram que WARP é sujeita à repressão traducional em macrogametócitos de P. berghei, com o seu mRNA sendo silenciado pela proteína DOZI através da formação de uma ribonucleoproteína. Os objetivos deste estudo foram i) Analisar o perfil de expressão da proteína WARP nos estágios sexuais de P. gallinaceum, ii) Comparar o perfil de transcrição de WARP, durante o desenvolvimento sexual, com perfis de alguns genes relacionados à regulação da expressão ou à invasão epitelial, e iii) Avaliar o potencial da proteína WARP como um candidato à vacina através da análise do seu padrão de expressão.

O domínio vWA de PfWARP foi produzido como uma proteína recombinante que foi usada para a produção de anticorpos policlonais. Foram realizados experimentos de microscopia confocal usando estes anticorpos para se detectar WARP em estágios sexuais cultivados de P. gallinaceum. RT-PCR foi usada para detectar WARP e os outros genes estudados a partir de amostras de sangue contendo gametócitos e a partir de intestinos de Aedes fluviatilis infectados, coletados até 24 horas após a alimentação. A proteína WARP pode ser detectada desde os estágios iniciais do desenvolvimento de oocinetos, em zigotos recém-fertilizados, até as formas maduras alongadas. Em zigotos, sua expressão parece ser intra-vesicular e localizada na periferia citoplasmática, próxima à membrana celular, e em oocinetos maduros, WARP apresenta uma distribuição granular com concentração focal na região apical, corroborando sua localização micronemal. Seu transcrito foi detectado, por RT-PCR, em gametócitos de P. gallinaceum. Ainda, o transcrito para a proteína PgDOZI também foi detectado em gametócitos, indicando que a repressão traducional possa ser um mecanismo de regulação gênica também nesta espécie, e que WARP seja, provavelmente, um de seus alvos de regulação. Esta é a primeira vez que a proteína WARP é detectada tão prematuramente durante o desenvolvimento de oocinetos e a primeira evidência de expressão dos genes DOZI, α-Tubulina e MAOP em P. gallinaceum.

A expressão de WARP, um alvo potencial para Vacinas de Bloqueio de Transmissão, durante o desenvolvimento sexual de Plasmodium gallinaceum / The Warp of expression, an potential target to vaccines of transmission of blockade, during the sexual development of Plasmodium gallinaceum

Durante o ciclo de vida dos parasitos causadores da malária, uma das fases cruciais é o desenvolvimento sexual e a conseqüente invasão do epitélio intestinal do hospedeiro invertebrado. Proteínas dos estágios do ciclo esporogônico podem ser alvos para vacinas Bloqueadoras de Transmissão (TBVs). Uma das proteínas micronemais que já demonstrou ser um alvo promissor para a inibição do desenvolvimento de oocistos e, portanto, da transmissão, é a WARP (von Willebrand Factor A Domain Related Protein), uma proteína secretada, aparentemente envolvida com a adesão e locomoção dos parasitos. Estudos recentes demonstraram que WARP é sujeita à repressão traducional em macrogametócitos de P. berghei, com o seu mRNA sendo silenciado pela proteína DOZI através da formação de uma ribonucleoproteína. Os objetivos deste estudo foram i) Analisar o perfil de expressão da proteína WARP nos estágios sexuais de P. gallinaceum, ii) Comparar o perfil de transcrição de WARP, durante o desenvolvimento sexual, com perfis de alguns genes relacionados à regulação da expressão ou à invasão epitelial, e iii) Avaliar o potencial da proteína WARP como um candidato à vacina através da análise do seu padrão de expressão.

O domínio vWA de PfWARP foi produzido como uma proteína recombinante que foi usada para a produção de anticorpos policlonais. Foram realizados experimentos de microscopia confocal usando estes anticorpos para se detectar WARP em estágios sexuais cultivados de P. gallinaceum. RT-PCR foi usada para detectar WARP e os outros genes estudados a partir de amostras de sangue contendo gametócitos e a partir de intestinos de Aedes fluviatilis infectados, coletados até 24 horas após a alimentação. A proteína WARP pode ser detectada desde os estágios iniciais do desenvolvimento de oocinetos, em zigotos recém-fertilizados, até as formas maduras alongadas. Em zigotos, sua expressão parece ser intra-vesicular e localizada na periferia citoplasmática, próxima à membrana celular, e em oocinetos maduros, WARP apresenta uma distribuição granular com concentração focal na região apical, corroborando sua localização micronemal. Seu transcrito foi detectado, por RT-PCR, em gametócitos de P. gallinaceum. Ainda, o transcrito para a proteína PgDOZI também foi detectado em gametócitos, indicando que a repressão traducional possa ser um mecanismo de regulação gênica também nesta espécie, e que WARP seja, provavelmente, um de seus alvos de regulação. Esta é a primeira vez que a proteína WARP é detectada tão prematuramente durante o desenvolvimento de oocinetos e a primeira evidência de expressão dos genes DOZI, α-Tubulina e MAOP em P. gallinaceum.

Genetic control of malaria parasite transmission: threshold levels for infection in an avian model system.

Genetic strategies for controlling malaria transmission based on engineering pathogen resistance in Anopheles mosquitoes are being tested in a number of animal models. A key component is the effector molecule and the efficiency with which it reduces parasite transmission. Single-chain antibodies (scFvs) that bind the circumsporozoite protein of the avian parasite, Plasmodium gallinaceum, can reduce mean intensities of sporozoite infection of salivary glands by two to four orders of magnitude in transgenic Aedes aegypti. Significantly, mosquitoes with as few as 20 sporozoites in their salivary glands are infectious for a vertebrate host, Gallus gallus. Although scFvs hold promise as effector molecules, they will have to reduce mean intensities of infection to zero to prevent parasite transmission and disease. We conclude that similar endpoints must be reached with human pathogens if we are to expect an effect on disease transmission.

Plasmodium development in white-eye (kh(w)) and transformed strains (kh43) of Aedes aegypti (Diptera: Culicidae).

Xanthurenic acid (XA) has been implicated as an inducer in vivo of exflagellation in Plasmodium spp. Consequently, the development of Plasmodium gallinaceum was assessed in a white-eye mosquito strain, kh(w), of Aedes aegypti (L.), which is deficient in XA because of a mutation of the gene encoding the enzyme kynurenine hydroxylase, and in a transformed line of kh(w) mosquitoes that carry the wild-type cn+ gene of Drosophila melanogaster Meigen and express a functional enzyme necessary for XA production. Although XA was not detectable in kh(w) mosquitoes by using high-pressure liquid chromatography with electrochemical detection, parasites were able to develop. Transformed kh(w) mosquitoes failed to consistently support parasite development at higher prevalences and mean intensities than did the nontransformed kh(w) lines, even though XA was detectable. These data suggest that factors other than XA may play a role in initiating Plasmodium development in vivo.

The efficacy of a mixture of trimethoprim and sulphaquinoxaline against Plasmodium gallinaceum malaria in the domesticated fowl Gallus gallus.

The apicomplexan parasite Plasmodium gallinaceum has not been much studied from the veterinary standpoint. Although it causes malaria in domesticated chickens, no effective drugs appear to be commercially available. A mixture of trimethoprim and sulphaquinoxaline (TMP/SQX, ratio 1:3), with a wide spectrum of activity against bacteria and coccidia, is here shown to be also efficacious against blood-induced P. gallinaceum malaria when administered therapeutically in the feed of chickens for 5-day periods, beginning on the day before infection, or on the day of infection, or up to four days after infection. Chickens were protected against mortality and reduction of weight gain. Three other criteria of efficacy, which showed good correlation with each other and also with the two commercial performance criteria, were the production of green diarrhoea (due to biliverdin), parasitaemia and reduced haematocrit values. When TMP/SQX treatments were initiated sooner than five days after infection, parasites were almost entirely eliminated from the blood, whereas treatments initiated later than four days after infection failed to protect birds against clinical disease. Birds protected by TMP/SQX against primary infection with P. gallinaceum were immune to clinical malaria when exposed to a severe blood-induced challenge of P. gallinaceum 28 days later.

Isonicotinic acid hydrazide: an anti-tuberculosis drug inhibits malarial transmission in the mosquito gut.

We studied the transmission-blocking effect of isonicotinic acid hydrazide (INH), a widely used anti-tuberculosis drug, against Plasmodium gallinaceum and Plasmodium berghei. INH-treatment of infected animals did not inhibit parasite development in the blood of the vertebrate host, but did inhibit exflagellation, ookinete formation, and oocyst development in the mosquito. Oocyst development was inhibited in a dose-dependent manner. The ED(50) in the P. gallinaceum/chicken/Aedes aegypti model and P. berghei/mouse/Anopheles stephensi model was 72 and 109 mg/kg, respectively. In marked contrast, in vitro exflagellation and ookinete development were not directly affected by physiological concentrations of INH. We suggest that INH exerts its inhibitory effects on the mosquito stages of the malaria parasite by an indirect, and at present undefined mechanism. Further elucidation of the mechanism how INH inhibits parasite development specifically on mosquito stages may allow us to identify new targets for malaria control strategy.

Linker scanning mutagenesis of the Plasmodium gallinaceum sexual stage specific gene pgs28 reveals a novel downstream cis-control element.

Protozoan parasites undergo complex life cycles that depend on regulated gene expression. However, limited studies on gene regulation in these parasites have repeatedly shown characteristics different from other eukaryotes. Within the Apicomplexa family, little is known about the mechanism of gene expression and regulation in Plasmodium spp. We have been investigating the cis-elements that control basal expression of a sexual stage specific gene in Plasmodium gallinaceum. Previously, we identified by 5' deletion analysis of a reporter construct that the 333bp upstream of the translational start site of pgs28 is sufficient for basal expression, and that the sequence between -333 and 316bp is necessary for such expression. In this report, we identified by linker scanning mutagenesis an 8-bp sequence that is essential for pgs28 transgene expression. This sequence is a target of sequence-specific nuclear factors. Primer extension studies demonstrate that, interestingly, the endogenous pgs28 transcript has two 5' ends, at -65 and +1. We suggest that this 8-bp sequence, CAGACAGC that is situated at +24 to +31 (with respect to the proximal start site), is a novel downstream promoter element in P. gallinaceum that appears to function independently of a TATA box or an Inr element.

Synthetic propeptide inhibits mosquito midgut chitinase and blocks sporogonic development of malaria parasite.

Incessant transmission of the parasite by mosquitoes makes most attempts to control malaria fail. Blocking of parasite transmission by mosquitoes therefore is a rational strategy to combat the disease. Upon ingestion of blood meal mosquitoes secrete chitinase into the midgut. This mosquito chitinase is a zymogen which is activated by the removal of a propeptide from the N-terminal. Since the midgut peritrophic matrix acts as a physical barrier, the activated chitinase is likely to contribute to the further development of the malaria parasite in the mosquito. Earlier it has been shown that inhibiting chitinase activity in the mosquito midgut blocked sporogonic development of the malaria parasite. Since synthetic propeptides of several zymogens have been found to be potent inhibitors of their respective enzymes, we tested propeptide of mosquito midgut chitinase as an inhibitor and found that the propeptide almost completely inhibited the recombinant or purified native Anopheles gambiae chitinase. We also examined the effect of the inhibitory peptide on malaria parasite development. The result showed that the synthetic propeptide blocked the development of human malaria parasite Plasmodium falciparum in the African malaria vector An. gambiae and avian malaria parasite Plasmodium gallinaceum in Aedes aegypti mosquitoes. This study implies that the expression of inhibitory mosquito midgut chitinase propeptide in response to blood meal may alter the mosquito's vectorial capacity. This may lead to developing novel strategies for controlling the spread of malaria.

The development of Plasmodium gallinaceum infections in chickens following single infections with three different dose levels.

In the present study, groups of 5-day-old chickens were inoculated intravenously with approximately 10(6), 10(4) or 10(2) P. gallinaceum-infected erythrocytes. The outcome of disease in relation to dose level was evaluated in terms of number of parasitized erythrocytes, change in number of erythrocytes, pathological changes of organs and the course of exo-erythrocytic stages of the parasite in various organs over a period of 8 weeks. Mean weight gain and mortality were also recorded. With regard to differences between the size of the inoculation dose and the severity of disease, relationships could be observed in relation to clinical signs, mortality, prepatent period, exo-erythrocytic parasites and severity of pathological changes in organs, but in relation to weight gain, erythrocyte loss and number of parasitized erythrocytes no relationships were observed.